References
- 1. T. Kino, H. Hatanaka, M. Hashimoto, M. Nishiyama, T. Goto, M. Okuhara, M. Kohsaka, H. Aoki and H. Imanaka, FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics, J. Antibiot.40 (1987) 1249–1255; https://doi.org/10.7164/antibiotics.40.124910.7164/antibiotics.40.1249
- 2. T. Kino, H. Hatanaka, S. Miyata, N. Inamura, M. Nishiyama, T. Yajima, T. Goto, M. Okuhara, M. Kohsaka, H. Aoki and T. Ochia, FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro, J. Antibiot.40 (1987) 1256–1265; https://doi.org/10.7164/antibiotics.40.125610.7164/antibiotics.40.1256
- 3. T. Goto, T. Kino, H. Hatanaka, M. Nishiyama, M. Okuhara, M. Kohsaka, H. Aoki and H. Imanaka, Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis, Transplant. Proc.19 (1987) 4–8.
- 4. J. J. Fung, Tacrolimus and transplantation: a decade in review, Transplantation77 (2004) S41-S43; https://doi.org/10.1097/01.TP.0000126926.61434.A510.1097/01.TP.0000126926.61434.A5
- 5. M. R. First, Tacrolimus based immunosuppression, J. Nephrol.17 (2004) S25–S31.
- 6. D. Simpson and S. Noble, Tacrolimus ointment – A review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions, Drugs65 (2005) 827–858; https://doi.org/10.2165/00003495-200565060-0001110.2165/00003495-200565060-00011
- 7. S. Dutta and Y. Ahmad, The efficacy and safety of tacrolimus in rheumatoid arthritis, Ther. Adv. Musculoskelet. Dis.3 (2011) 283–291; https://doi.org/10.1177/1759720X1141903810.1177/1759720X11419038
- 8. D. M. Skytte, J. W. Jaroszewski, K. T. Johansen, S. H. Hansen, L. Hansen, P. G. Nielsen and K. Frydenvang, Some transformations of tacrolimus, an immunosuppressive drug, Eur. J. Pharm. Sci.48 (2013) 514–522; https://doi.org/10.1016/j.ejps.2012.12.00110.1016/j.ejps.2012.12.001
- 9. H. Ok, B. H. Arison, R. G. Ball, T. R. Beattie, M. H. Fisher and M. J. Wyvratt, Thermal rearrangement of the immunosuppressant FK-506, Tetrahedron Lett.31 (1990) 6477–6480; https://doi.org/10.1016/S0040-4039(00)97095-310.1016/S0040-4039(00)97095-3
- 10. D. M. Skytte, K. Frydenvang, L. Hansen, P. G. Nielsen and J. W. Jaroszewski, Synthesis and characterization of an epimer of tacrolimus, an immunosuppressive drug, J. Nat. Prod.73 (2010) 776–779; https://doi.org/10.1021/Np900797510.1021/np900797520166703
- 11. P. Ferraboschi, D. Colombo, M. De Mieri and P. Grisenti, Evaluation, synthesis and characterization of tacrolimus impurities, J. Antibiot.65 (2012) 349–354; https://doi.org/10.1038/Ja.2012.2810.1038/ja.2012.2822511227
- 12. C. D. Sommers, E. S. Pang, H. Ghasriani, R. T. Berendt, V. L. Vilker, D. A. Keire and M. T. Boyne, 2nd, Analyses of marketplace tacrolimus drug product quality: bioactivity, NMR and LC-MS, J. Pharm. Biomed. Anal.85 (2013) 108–117; https://doi.org/10.1016/j.jpba.2013.07.00110.1016/j.jpba.2013.07.00123917038
- 13. T. Rozman Peterka, R. Grahek, J. Hren, A. Bastarda, J. Bergles and U. Urleb, Solid state compatibility study and characterization of a novel degradation product of tacrolimus in formulation, J. Pharm. Biomed. Anal.110 (2015) 67–75; https://doi.org/10.1016/j.jpba.2015.02.04710.1016/j.jpba.2015.02.047
- 14. United State Pharmacopeia 41, National Formulary 36, US Pharmacopeial Convention, Rockville 2018, pp. 3906–3914; https://online.uspnf.com/uspnf; last access date December 24, 2018.
- 15. European Pharmacopoeia 9.3, Council of Europe, Strasbourg 2018, pp. 4997–4999; http://online6.edqm.eu/ep905/; last access date December 24, 2018.
- 16. T. Akashi, T. Nefuji, M. Yoshida and J. Hosoda, Quantitative determination of tautomeric FK506 by reversed-phase liquid chromatography, J. Pharm. Biomed. Anal.14 (1996) 339–346; https://doi.org/10.1016/0731-7085(95)01605-810.1016/0731-7085(95)01605-8
- 17. Y. Namiki, N. Kihara, S. Koda, K. Hane and T. Yasuda, Tautomeric phenomenon of a novel potent immunosuppressant (FK506) in solution I. Isolation and structure determination of tautomeric compounds, J. Antibiot.46 (1993) 1149–1155; https://doi.org/10.7164/antibiotics.46.114910.7164/antibiotics.46.11497689551
- 18. Y. Namiki, A. Fujiwara, N. Kihara, S. Koda, K. Hane and T. Yasuda, Determination of the immunosuppressive drug tacrolimus in its dosage forms by high-performance liquid-chromatography, Chromatographia40 (1995) 253–258; https://doi.org/10.1007/Bf0229035410.1007/BF02290354
- 19. Q. Shi, J. Li and F. Ding, Development and validation of method for the determination of related substances of tacrolimus in tacrolimus capsules and degradation studies, Int. J. ChemTech Res.4 (2012) 1543–1552.
- 20. A. Subasranjan, C. Srinivasulu and R. Hemant, An improved validated ultra high pressure liquid chromatography method for separation of tacrolimus impurities and its tautomers, Drug Test. Anal.2 (2010) 107–112; https://doi.org/10.1002/dta.11210.1002/dta.11220878891
- 21. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Current Step 4 version, October 1994 (parent), November 1996 (complementary); http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf; last access date September 19, 2018.
- 22. N. S. Trasi, H. S. Purohit and L. S. Taylor, Evaluation of the crystallization tendency of commercially available amorphous tacrolimus formulations exposed to different stress conditions, Pharm. Res.34 (2017) 2142–2155; https://doi.org/10.1007/s11095-017-2221-410.1007/s11095-017-2221-428687987